Tackling the Tuberculosis Burden in Children: A Global Perspective

By Crystal Lubbe

March 12, 2025

Did you know the global burden of tuberculosis (TB) among children has dropped significantly over the past three decades? A recently published article analyses the global tuberculosis burden children face. It details the situation from 1990 to 2021 using data from the Global Burden of Disease Study 2021. The report shows a significant decrease in TB incidence, mortality, and disability-adjusted life years (DALYs) over this period. However, regional and socioeconomic disparities remain notable. Despite progress, tuberculosis continues to pose a major public health threat, especially in areas with a low socio-demographic index (SDI).

Key Insights

  • Decline in TB Burden: The global TB incidence among children and adolescents decreased by 37.4% from 1990 to 2021. Deaths also dropped by 71.7%.
  • Regional Disparities: Regions with low SDI, such as parts of Africa, still face a high tuberculosis burden in children disproportionately. High-income regions, however, have seen substantial reductions.
  • Sex Differences: Females under 20 have higher age-standardised incidence rates (ASIR), mortality rates (ASMR), and DALY rates compared to males.
  • Drug Resistance: Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) among children and adolescents are growing concerns.

Background Context

The World Health Organization (WHO) is working to end TB through its End TB Strategy. This strategy aims to reduce TB incidence and mortality by defined targets. Progress has been slow, especially in children and adolescents, where TB remains a major cause of morbidity and mortality. The COVID-19 pandemic has further complicated TB control efforts. It disrupted healthcare services and led to underreporting of TB cases. For detailed analysis, see here.

Implications

The findings have important implications for health economics and outcomes research:

  • Healthcare Infrastructure: Investing in healthcare infrastructure, especially in low SDI regions, is crucial for improving TB diagnosis and treatment.
  • Socioeconomic Interventions: Addressing factors like poverty and malnutrition can help reduce TB transmission.
  • Drug Resistance Management: Effective strategies are needed to manage drug-resistant TB and prevent its spread among vulnerable populations.
  • Research and Development: More research into pediatric TB diagnostic tools and treatment formulations is urgently needed to improve outcomes for children and adolescents.
Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.